Key clinical point: Serotonin-norepinephrine reuptake inhibitors (SNRIs) are clinically safe and effective, and non-inferior to other active drugs for the prophylaxis of migraine and vestibular migraine (VM).
Major finding: Fewer migraine days were reported with SNRIs vs placebo (standardized mean difference [SMD] -0.38; P = .04). In patients with VM, venlafaxine had a significant advantage in decreasing the vertigo severity score (weighted mean difference (MD) -1.45; P less than .0001) and emotional domain score of dizziness handicap inventory (MD -2.64; P = .03) vs other active drugs. No significant difference was noted in withdrawal rates between the groups.
Study details: Meta-analysis of six randomized controlled trials including 418 participants.
Disclosures: This study was funded by the Natural Science Foundation of Liaoning Province. The authors declared no conflicts of interests.
Citation: Wang F et al. Reg Anesth Pain Med. 2020 March. doi: 10.1136/rapm-2019-101207